Replies to post #35879 on OncoSec Medical Inc (ONCSQ)

[ahab333]

Notice they did say refractory again. I put in red below and thanks Titan

GLTA

HCIT

LINK: https://bif16.eventsbio.com/connect/search.ww

OncoSec Medical Incorporated OncoSec is pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Our mission is to deliver safer and more effective cancer treatments that can provide long-term benefits for patients through our proprietary technology. OncoSec's core immunotherapy platform, ImmunoPulse, is designed to deliver DNA-based therapeutics directly into tumors and reverse the immuno-suppressive tumor microenvironment. Our lead program, ImmunoPulse IL-12, employs this intratumoral technology to enhance the local expression of interleukin-12 (IL-12). ImmunoPulse IL-12 is currently in clinical development for several indications including metastatic melanoma and triple-negative breast cancer. This includes our Phase II combination trial of ImmunoPulse IL-12 and Merck’s anti-PD-1 drug KEYTRUDA in patients with metastatic melanoma. The program’s current focus is on the significant unmet medical need in refractory and non-responders to anti-PD-1/PD-L1 therapies in melanoma. In Phase I and II clinical trials, ImmunoPulse IL-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors and has shown the potential to reach beyond the site of local treatment to initiate a systemic immune response. In addition to ImmunoPulse IL-12, OncoSec is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform.
View Less
Company Presentation
Punit Dhillon
Scheduling Options

[chickpea598]

Liam Ratcliffe, MD, PhD, Managing Director, New Leaf Venture Partners will be involved in this. I like that. Would be nice to see an investment from New Leaf in Oncosec.